Blog

Jorge Cortes: Olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax

Photo from Jorge Cortes/X

Aug 18, 2024, 15:03

Jorge Cortes: Olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax

Jorge Cortes, Director of the Georgia Cancer Center, shared on X about recent paper by him as first author titled “Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)” published on Taylor and Francis Online.

Authors: Jorge Cortes, Brian A. Jonas, Gary Schiller, Alice Mims, Gail J. Roboz, Andrew H. Wei, Pau Montesinos, P. Brent Ferrell, Karen WL. Yee, Pierre Fenaux, Anthony Schwarer and Justin M. Watts

“Published the experience with olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax. Small series but providing useful information for a common scenario in the clinic.”

Source: Jorge Cortes/X

Alice Mims Andrew H. Wei Anthony Schwarer Anthony Schwarer and Justin M. Watts Brian A. Jonas cancer Gail J. Roboz Gary Schiller Jorge Cortes Justin M. Watts Karen WL. Yee Olutasidenib OncoDaily Oncology P. Brent Ferrell Pau Montesinos Pierre Fenaux Taylor and Francis Online venetoclax

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer